Lynparza approved in the EU for 1st-line
18 June 2019 07:00 BST Lynparza approved in the EU for 1st-line maintenancetreatment of BRCA-mutated advanced ovarian cancer 60% of patients receiving Lynparza remained free of disease progressionafter three years vs. 27% on placebo in pivotal Phase III SOLO-1 trial AstraZeneca and MSD's Lynparza is the only PARPinhibitor approved in the EU for this indication AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the European Commission (EC) has approved Lynparza (olaparib) as a 1st-line maintenance